Panel Abuses Purdue Over OxyContin
This article was originally published in The Pink Sheet Daily
Executive Summary
Tamper-resistant version would lead to more problems, say FDA advisors.
You may also be interested in...
Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
FDA Advisors Question Impact of OxyContin Improvements Due To Generics
Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin
FDA Advisors Question Impact of OxyContin Improvements Due To Generics
Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin